For disclosure I hold both DXB & PAA, and have Buy sentiment on both.
My suggestion and request is when you compare two companies can we use more than SP to compare attractiveness such as market cap (MC), phase of trial, closeness to regulatory approval, commercial arrangements etc? I am not trying to cross-promote DXB but if I evaluate on these parameters then I consider DXB a bit ahead of the game currently. Who knows where we will be in 6 months.
If you can use multiple parameters and lay out your rationale that can make for more interesting reading over the weekend. Thanks.
No advice. DYOR.
Ann: OLE Study update reveals impressive Survival Data, page-131
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $94.89M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 19.0¢ | $58.40K | 305.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 115000 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 86074 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |